Size | Price | |
---|---|---|
Other Sizes |
ln Vitro |
Growth inhibition is time-and dose-dependent for silybin (0-200 mM; for 72 hours)[1]. Silybin (68 μM; for 72 hours) causes apoptosis and raises the percentage of cells in the G1 phase to about 22% [1]. AKT activity inhibition is induced by silybin (68 μM) for a duration of 72 hours[1].
|
---|---|
ln Vivo |
For the last four weeks, silybin (50–100 mg/kg/day; administered intragastrically) has been shown to dramatically reduce hepatic and serum lipid accumulation[2].
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: HepG2 cell growth Tested Concentrations: 0-200 mM Incubation Duration: For 72 hrs (hours) Experimental Results: Had growth inhibition in a time- and dose-dependent manner with an IC50 of 68 μM. Apoptosis Analysis[1] Cell Types: HepG2 cell growth Tested Concentrations: 68 μM Incubation Duration: For 72 hrs (hours) Experimental Results: Induced apoptosis in a higher number of cells (60%) when compared to untreated cells. Cell Cycle Analysis[1] Cell Types: HepG2 cell growth Tested Concentrations: 68 μM Incubation Duration: For 72 hrs (hours) Experimental Results: Increased the cells in G1-phase of ~22% and diminished of 47% the cells in S-phase. Western Blot Analysis[1] Cell Types: HepG2 cell growth Tested Concentrations: 68 μM Incubation Duration: For 72 hrs (hours) Experimental Results: Induced AKT activity inhibition. |
Animal Protocol |
Animal/Disease Models: Male C57BL/6J mice (6-8 weeks old) with nonalcoholic fatty liver disease (NAFLD)[2]
Doses: 50, 100 mg/kg Route of Administration: Given intragastrically (po); daily; for the last 4 weeks Experimental Results: Dramatically lowered both serum and hepatic lipid accumulation. |
References |
[1]. Silvia Zappavigna, et al. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. Int J Mol Sci. 2019 May 3;20(9):2190.
[2]. Runbin Sun, et al. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother. 2020 Mar;123:109721. |
Molecular Formula |
C25H22O10
|
---|---|
Molecular Weight |
482.44
|
CAS # |
802918-57-6
|
Related CAS # |
Silybin A;22888-70-6;Isosilybin;72581-71-6;Silybin B;142797-34-0
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
COC1=C(C=CC(=C1)C2C(CO)OC3=C(C=C(C=C3)[C@@H]4[C@H](C(=O)C5=C(C=C(C=C5O4)O)O)O)O2)O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 25 mg/mL (51.82 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0728 mL | 10.3640 mL | 20.7280 mL | |
5 mM | 0.4146 mL | 2.0728 mL | 4.1456 mL | |
10 mM | 0.2073 mL | 1.0364 mL | 2.0728 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.